| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PLRX | Common Stock | Award | $0 | +68.8K | +115.99% | $0.00 | 128K | Dec 19, 2022 | Direct | F1 |
| transaction | PLRX | Common Stock | Sale | -$654K | -34.2K | -26.72% | $19.10 | 93.8K | Dec 20, 2022 | Direct | F2 |
| holding | PLRX | Common Stock | 449K | Dec 19, 2022 | See footnote | F3 |
| Id | Content |
|---|---|
| F1 | On July 28, 2022, the Reporting Person was granted 275,000 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On December 19, 2022, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 68,751 shares. |
| F2 | The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker at prices ranging from $18.4049 to $19.64, inclusive, on December 20, 2022 and December 21, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (2) to this Form 4. |
| F3 | Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |